The opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is Innovent’s first European regulatory milestone; if approved, Zybrivo would expand first-line treatment options for eligible patients with lung cancer in Europe

PALO ALTO, Calif. and SUZHOU, China, Nov. 16, 2026 /PRNewswire/ — Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces it has received its first positive opinion from the CHMP of the European Medicines Agency (EMA). The CHMP recommends marketing authorization of Zybrivo® (sintilimab), in combination with chemotherapy, for adults with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo would provide eligible patients across Europe with access to another first-line treatment option. The positive opinion is supported by results from the Phase 3 ORIENT-11 study (NCT03607539).